{"url_path":"/sec/jspr/8-k/2026-07-16/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-078781-index.html","accession_number":"0001213900-26-078781","cik":"0001788028","ticker":"JSPR","issuer_name":"Jasper Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1788028/0001213900-26-078781-index.html","primary_entity_key":"0001788028","primary_entity_name":"Jasper Therapeutics, Inc."},"word_count":192,"has_tables":true,"body_markdown":"**Item 7.01 - Regulation FD Disclosure.**\n\n** **\n\nOn July 16, 2026, Jasper Therapeutics, Inc. (the “Company”)\nissued a press release announcing that the Company has completed the acquisition of Kira Pharmaceuticals, a former Cayman limited company\nthat was engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction and entered into\na securities purchase agreement for a  private placement financing for gross proceeds of $132 million. A copy of the press release\nis furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe information in Item 7.01 of this Current Report on Form 8-K, including\nthe information in the press release attached as Exhibit 99.1, are furnished pursuant to Item 7.01 of Form 8-K and\nshall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise\nsubject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, including\nExhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of\nthe Company under the Securities Act."}